Certified by Founder
Lodge
Initial Therapeutics
start up
United States
- South San Francisco, California
- 02/05/2023
- Series A
- $75,000,000
Initial Therapeutics is discovering and developing a new class of small-molecule medicines designed to halt pathogenic protein formation in the earliest stages.
Initial’s approach is unique and starkly differentiated from protein degradation and other interventions that recognize and tackle proteins only after they have been fully formed.
- Industry Biotechnology Research
- Website https://initialtx.com/
- LinkedIn https://www.linkedin.com/company/initial-therapeutics/people/
Tolemy Bio | $1,643,411 | (May 13, 2026)
Basata | $21,000,000 | (May 13, 2026)
Corvera (YC W26) | $4,200,000 | (May 13, 2026)
4AM | $4,000,000 | (May 13, 2026)
Ciridae | $20,000,000 | (May 13, 2026)
Sedivention - Freezing the hunger feeling | $3,402,541 | (May 13, 2026)
Meatly | $14,074,996 | (May 13, 2026)
NanoStruct GmbH | $3,050,853 | (May 13, 2026)
Adfin | $18,000,000 | (May 13, 2026)
Boundary | $2,000,000 | (May 13, 2026)
Algorithmiq | $21,122,550 | (May 13, 2026)
Knit Health | $11,600,000 | (May 13, 2026)